Search

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)
EU-U.S., SWISS-U.S. AND UK EXTENSION TO THE EU-U.S. DATA PRIVACY FRAMEWORK PRIVACY POLICY
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Investigator-Initiated Studies
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
Sarepta Therapeutics anuncia los destinatarios de la 7ª edición anual de Route 79, el programa de becas de Duchenne, para el año académico 2024-2025